Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RegStem in Knee Osteoarthritis
NCT03007576Phase 1Completed
- Sponsor
- EMO Biomedicine
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RegStem in osteoarthritis (OA), sponsored by EMO Biomedicine. Primary endpoints: Safety of RegStem at 48 weeks and International Knee Documentation Committee Score at 48 weeks. Started Aug 2017; status: completed.
02
Drugs
RegStem
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03007576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007576.